EP4041237 - TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.07.2022 Database last updated on 02.09.2024 | |
Former | The international publication has been made Status updated on 17.04.2021 | Most recent event Tooltip | 01.08.2024 | New entry: Decision on request for further processing | Applicant(s) | For all designated states G1 Therapeutics, Inc. 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 / US | [2022/33] | Inventor(s) | 01 /
STRUM, Jay Copeland 616 Deerhaven Court Hillsborough, NC 27278 / US | 02 /
WHITWORTH, Chloe c/o G1 Therapeutics, Inc. 700 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 / US | 03 /
FREED, Daniel M. c/o G1 Therapeutics, Inc. 700 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 / US | [2022/33] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2022/33] | Application number, filing date | 20874071.2 | 09.10.2020 | [2022/33] | WO2020US55146 | Priority number, date | US201962913055P | 09.10.2019 Original published format: US 201962913055 P | [2022/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021072319 | Date: | 15.04.2021 | Language: | EN | [2021/15] | Type: | A1 Application with search report | No.: | EP4041237 | Date: | 17.08.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.04.2021 takes the place of the publication of the European patent application. | [2022/33] | Search report(s) | International search report - published on: | US | 15.04.2021 | (Supplementary) European search report - dispatched on: | EP | 27.09.2023 | Classification | IPC: | A61K31/498, A61K31/519, A61K31/506, A61P35/00, A61K45/06 | [2023/43] | CPC: |
A61K45/06 (EP,CN,KR,US);
A61K31/519 (EP,CN,KR,US);
A61K31/498 (EP,CN,KR,US);
A61P35/00 (EP,CN,KR,US);
A61K2300/00 (KR)
| C-Set: |
A61K31/498, A61K2300/00 (CN,EP);
A61K31/519, A61K2300/00 (CN,EP) |
Former IPC [2022/33] | A61K31/506, A61K31/519, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/33] | Title | German: | GEZIELTE BEHANDLUNG VON KREBS MIT DYSREGULIERTER FIBROBLASTENWACHSTUMSFAKTORREZEPTORSIGNALISIERUNG | [2022/33] | English: | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | [2022/33] | French: | TRAITEMENT CIBLÉ DE CANCERS AVEC UNE SIGNALISATION DE RÉCEPTEUR DE FACTEUR DE CROISSANCE DES FIBROBLASTES DÉRÉGULÉE | [2022/33] | Entry into regional phase | 09.05.2022 | National basic fee paid | 09.05.2022 | Search fee paid | 09.05.2022 | Designation fee(s) paid | 09.05.2022 | Examination fee paid | Examination procedure | 09.05.2022 | Examination requested [2022/33] | 23.05.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 23.07.2024 | Amendment by applicant (claims and/or description) | 23.07.2024 | Date on which the examining division has become responsible | Request for further processing for: | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 23.07.2024 | Request for further processing filed | 23.07.2024 | Full payment received (date of receipt of payment) Request granted | 31.07.2024 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 23.07.2024 | Request for further processing filed | 23.07.2024 | Full payment received (date of receipt of payment) Request granted | 31.07.2024 | Decision despatched | Fees paid | Renewal fee | 09.05.2022 | Renewal fee patent year 03 | 24.08.2023 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]CA3054455 (BETTA PHARMACEUTICALS CO LTD [CN]) [Y] 1-17* p. 121, table 9 *; | [Y]WO2019136451 (G1 THERAPEUTICS INC [US]) [Y] 1-17 * p. 3, l. 29 to p. 4, l. 3; p. 5, l. 2-5; p. 7, l. 3-12, p. 37, l. 12; p. 38, l. 7; p. 41, l. 27; p. 93, l. 16-25 *; | [Y] - Sorrentino Jessica, "The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer", (20180701), URL: https://aacrjournals.org/cancerres/article/78/13_Supplement/1522/625777/Abstract-1522-The-CDK4-6-inhibitor-G1T38-enhances, (20210927), XP055845057 [Y] 1-17 * the whole document * | [Y] - MAHIPAL AMIT ET AL, "FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 78, doi:10.1016/J.CTRV.2019.06.003, ISSN 0305-7372, (20190622), pages 1 - 7, (20190622), XP085782604 [Y] 1-17 * p. 1, left col. last sentence; chapter FGFR aberrations in cholangiocarcinoma; chapter Selective small molecule TKIs; Table 3 * DOI: http://dx.doi.org/10.1016/j.ctrv.2019.06.003 | International search | [A]US2012237511 (LONG LI [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160) * ; entire document *; | [A]US2012251538 (HARDING THOMAS [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160)* ; entire document *; | [YA]WO2019006393 (G1 THERAPEUTICS INC [US]) [Y] 120, 123/120, 140, 143/140, 160, 163/160 * ; pg. 2, In 1-5, pg. 69, In 13-14, pg. 71, In 28 * [A] 1-6, 34-36, 62-64, 75-78, 115, 117-119, 123/(115, 117-119), 135, 137-139, 143/(135, 137-139), 155- 159, 163/(155-159); | [A]US2019175598 (SELVARAJ ANAND [US], et al) [A] 1-6, 34-36, 62-64, 75-78,115, 117-120, 123/(115,117-120), 135, 137-140,143/(135, 137-140), 155-160, 163/(155-160) * ; abstract, para [0004], [0012], [0023] *; | [YA] - Loriot Yohann, Necchi Andrea, Park Se Hoon, Garcia-Donas Jesus, Huddart Robert, Burgess Earle, Fleming Mark, Rezazadeh Arash, Mellado Begoña, Varlamov Sergey, Joshi Monika, Duran Ignacio, Tagawa Scott T., Zakharia Yousef, Zhong Bob, Stuyckens Kim, Santiago-Walker Ademi, De Porre Peter, O’hagan Anne, Avadhani Anjali, Siefker-Radtke Arlene O., "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma", The New England journal of medicine, US , (20190725), vol. 381, no. 4, doi:10.1056/NEJMoa1817323, ISSN 0028-4793, pages 338 - 348, XP055920378 [Y] 120, 123/120, 140,143/140, 160, 163/160 * ; pg. 338, para 1, pg. 339, right col, para 3 * [A] 1-6, 34-36, 62-64, 75-78,115, 117-119, 123/(115,117-119), 135, 137-139,143/(135, 137-139), 155-159, 163/(155-159) DOI: http://dx.doi.org/10.1056/NEJMoa1817323 |